Latest Financial Reporting News

Saluda Medical’s Australian arm has secured ASIC approval to bypass standalone audited financial reports, cutting costs and streamlining compliance.

Novo Resources narrowed its Q1 2026 net loss to CAD 685K, boosted cash to CAD 10.6M following a $5.9M placement, and outlined aggressive gold and antimony drilling campaigns in Australia.

Marimaca Copper Corp. reported a robust cash position of $147.7 million in Q1 2026, driven by a C$409 million equity raise, supporting ongoing development of its Marimaca Project in Chile.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Almonty Industries reported a 221% jump in Q1 2026 revenue to CAD 25.4 million, driven by soaring tungsten prices and ramp-up at its Sangdong Mine, while net loss narrowed to CAD 5.3 million amid strong operational cash flow.

Ainsworth Game Technology has confirmed Ryan Comstock as CEO after six months as acting chief, tying his pay to company performance through incentive plans.

Temas Resources’ 2026 re-assays of 2022 drill samples at La Blache reveal material uplifts in vanadium, gallium, scandium, and chromium grades, strengthening the case for its proprietary Regenerative Chloride Leach technology.

Navigator Global Investments (ASX: NGI) has kicked off a fully underwritten entitlement offer to raise A$145 million, supporting its US$195 million acquisition of a portfolio of alternative asset manager stakes from Stable Asset Management.

Critical Resources Limited (ASX:CRR) has initiated a pro-rata entitlement offer of Loyalty Options priced at $0.001 each, aiming to raise $319,410 and potentially $2.56 million upon exercise. The offer underscores significant dilution and operational risks amid ongoing exploration and legal challenges.

NeuRizer Ltd advanced its urea project with Reliance Industries payments and environmental submissions, despite ongoing ASX trading suspension and overdue financial reports.

Merino & Co. reported Q3 FY26 revenue of A$441,558 with new domestic and China purchase orders supporting its growth strategy, while cash reserves fell to A$654,282 due to investments in production and marketing.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.